

## **Helix BioMedix and Grant Industries Advance Collaborative Partnership for Innovative Application of Cosmetic Peptide Technology**

*Sep 18, 2007 - Bothell, Washington and Elmwood Park, New Jersey*

Helix BioMedix, Inc. (OTCBB: HXBM) and Grant Industries, Inc. announced today a modification of a license agreement designating Grant Industries as the exclusive licensee of two anti-aging peptides, palmitoyl-Hexapeptide-6 and Hexapeptide-21.

"We've been impressed with Grant's vision for these two peptides," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix, Inc. "Their appreciation of the potential for palmitoyl-Hexapeptide-6, in particular, has taken it beyond just an ingredient and evolved it to a platform technology that has many beneficial applications in the marketplace."

David Granatell, Executive Director of Grant Industries, stated, "Our objective has been to tailor ingredient blends and application formats with Helix BioMedix's peptides to help brand marketers leverage the technology in ways that are consistent with their unique positions in the marketplace. We have applied palmitoyl-Hexapeptide-6 in some very creative formulations and have even been able to instill anti-aging peptide benefits to cosmetic powders through a proprietary process we've developed. These anti-aging formulas are in addition to a product line we've formulated with Helix BioMedix's patented Oligopeptide-10, a cosmetic ingredient for acne-prone skin. We currently have numerous new products that apply palmitoyl-Hexapeptide-6 under development, which we expect to launch in 2007 or 2008 in the United States, Canada, Asia and Europe."

Today, Grant's ingredient blends with palmitoyl-Hexapeptide-6 may be found in a variety of products from skin care creams, lotions and serums, to liquid make-up foundations and mineral powders. Proprietary products containing the peptide are currently sold through mass, prestige and direct response channels by leading brand marketers.

### **About Helix BioMedix, Inc.**

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. More information about Helix BioMedix and its proprietary peptides may be found on the company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

### **Forward-Looking Statements**

This press release contains forward-looking statements regarding Helix BioMedix, Inc. (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties

are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the Helix BioMedix, Inc. website or at [www.sec.gov](http://www.sec.gov). Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. Helix BioMedix, Inc. undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

**About Grant Industries, Inc.**

Grant Industries is a family owned company involved in the research, development, manufacturing, and marketing of specialty chemicals for the cosmetic, textile, and printing industries.

**Forward-Looking Statements**

This press release contains forward-looking statements regarding Helix BioMedix, Inc. (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the Helix BioMedix, Inc. website or at [www.sec.gov](http://www.sec.gov). Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. Helix BioMedix, Inc. undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

**Helix BioMedix Contacts:**

**Investor Contact:**

Ryan Bright  
Shelton Group Investor Relations  
972-239-5119 X 159  
[rbright@sheltongroup.com](mailto:rbright@sheltongroup.com)

**Company Contact:**

R. Stephen Beatty  
President and CEO  
425-402-8400  
[sbeatty@helixbiomedix.com](mailto:sbeatty@helixbiomedix.com)

**Grant Industries Contacts:**

**Company Contact:**

Paul Granatell  
Executive Director

(201) 791-8700

[pgranatell@grantinc.com](mailto:pgranatell@grantinc.com)